

H1000.H15C Lot No. HC4-5

Cryopreserved Human Hepatocytes

Donor Information

DemographicsSerologyGender:MaleCMV: (+)Age:59 YearsHIV: (-)Race:African AmericanHBV: (-)Cause of Death:Cerebrovascular AccidentHCV: (-)

Assured Minimum Yield: 6.0 x 10⁶ per vial

Viability: 71.3%

(Yield and viability are based on experiments performed at XenoTech using XenoTech's thawing protocol and Hepatocyte Isolation Kit.)

Enzyme	Marker substrate reaction (pmol/cells per inc/min)	
CYP1A2	Phenacetin <i>O</i> -dealkylation	82.2 ± 5.1
CYP2A6	Coumarin 7-hydroxylation	49.9 ± 11.7
CYP2B6	Bupropion hydroxylation	245 ± 7
CYP2C8	Amodiaquine N-dealkylation	296 ± 22
CYP2C9	Diclofenac 4'-hydroxylation	602 ± 78
CYP2C19	S-Mephenytoin 4'-hydroxylation	30.6 ± 2.8
CYP2D6	Dextromethorphan O-demethylation	84.2 ± 10.0
CYP2E1	Chlorzoxazone 6-hydroxylation	223 ± 20
CYP3A4/5	Testosterone 6β-hydroxylation	980 ± 143
CYP3A4/5	Midazolam 1'-hydroxylation	232 ± 15

CAUTION: These hepatocyte samples are from donors who tested negative for HIV and hepatitis. However, we recommend that these samples be considered as potential biohazards and that universal precautions be used when working with human derived products.

Store vials in liquid nitrogen, vapor phase.



Data sheet prepared 9 Sept 09